🔗 Share this article

Given that the United States continues making sweeping revisions to its vaccination guidelines, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on Covid vaccines throughout the global health crisis and has zeroed in on possible fatalities following Covid immunization in her short time at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Public health authorities had intended to reveal major revisions to the childhood immunization program in December, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the global community with little proof for benefit. The announcement has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood shot schedules in the US so as to align more similar to Denmark, a country with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – usually the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no apparent background in medication creation, approval processes or management, which has been typical for previous directors of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for overseeing the CDER, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

CDER has an enormous portfolio at the FDA, she pointed out.

“Many people just focuses on the new drug program, but the generic drug division approves thousands of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and every single one must be supervised,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant management aspect to the role, which supervises more than 5,000 personnel. “It is a huge leadership role, if you execute it properly,” the former official added.

Response and Disputed Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this assignment represents more teamwork among regulatory chiefs on immunizations, a representative stated that the “questions stem from inaccurate presumptions”.

“Her experience matches the responsibilities of her position,” the representative stated, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s new expedited review system, a controversial rapid therapy clearance system that apparently worried her former heads. “By what process are these medications being chosen for this voucher program? Who takes the decisions?” Howard said. “There is a lot of secrecy going on at the FDA right now.”

Overall, he said, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a clearer, if concerning, track record, Howard said. She published a study using non-validated crowd-sourced reports to determine the rate of heart inflammation following COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the current administration featured revising regulations for novel immunizations and discontinuing “non-essential” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has reportedly proposed excluding adolescent males from obtaining Covid vaccinations.

“She’s an all-around true believer who commences with her conclusions and reverse-engineers to accommodate the science in a extremely disingenuous, dishonest way,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|